Potentials of the Cuban biopharmaceutical industry

Alfredo Nieves Portuondo

Unique medicines of its kind in the world such as Heberprot-P, the CIMAvax-EGF vaccine, as well as the creation of therapies for the treatment of diseases of the central nervous system, cancer, hepatitis B or meningoencephalitis have turned Cuba into a world power in biotechnology.

In this opportunity, we present the Cuban company BioCubaFarma responsible for developing joint projects in the field of biotechnology and the production of medicines against cancer and other diseases.

Cuba shows in UNICEF its strategy to develop the vaccine industry

Headquarter of United Nations Children's Fund (UNICEF), Copenhagen

From 2 to 6 October 2017, the United Nations Children's Fund (UNICEF) in Copenhagen hosted the Vaccine Acquisition Professionals Exchange Forum and the UNICEF Annual Consultation with the Global Vaccine Industry, respectively. Cuba was present in both appointments, represented by MsC Danev Ricardo Pérez Valerino, Head of International Relations of the Finlay Institute of Vaccines, belonging to the BioCubaFarma Business Group.

Subscribe to Biocubafarma